TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
The Journal of clinical investigation 2018 06 26() doi 10.1172/JCI96393 Abstract Dormant or slow-cycling tumour cells can form a residual chemoresistant reservoir responsible for relapse in patients, years after curative surgery...
Read More